Cellular Therapies

Aim

raise awareness of cellular therapies and support their improvement globally within Transfusion Medicine

Cellular Therapy involves utilization of cells for treatment including haematopoietic stem cell transplantation (HSCT). HSCT may enable stem and progenitor cells to be engrafted, replacing the bone marrow of the recipient completely. Other examples include bone marrow-derived mesenchymal stromal cells, embryonic or induced pluripotent stem cells (iPs) and specific T-lymphocytic cell lines which can differentiate into a variety of cells. In the future this might also include the ex-vivo expansion of cord blood into red blood cells, platelets and their progenitors. Novel blood-derived therapeutics include platelet lysates, amniopatch and serum eye drops.

About

We cover all the different aspects of (novel) cellular therapies. We foster collaboration amongst ISBT members, promote investigation and initiate projects including guidelines and standards. We act as an expert group to advise ISBT and cooperate with the AABB Cell therapy Working Group. We provide a platform for discussion, especially when related to transfusion and provide a resource for learning and the exchange of ideas.

Our Chairperson is Mickey Koh.

 

Activities

We meet at the ISBT congresses and initiate collaborative projects. We advise and represent ISBT on global issues regarding cellular therapy and collaborate with AABB's Cellular Therapy Group.

Joining the WP

Our WP currently comprises mostly of medical professionals including haemato-oncologists, infectious disease experts, doctors, nurses and scientists working in the area of cell and tissue regeneration. But other interested individuals (regulatory affairs, specialized nurses, quality managers or scientists) are also eligible to join.

Interested in joining the Cellular Therapies WP? Please email our Chairperson.

 

MORE

Meetings

Some of the content is only accessible for ISBT-members.
To join us, click here.

Topics and activities

Our main aim is to bring current and best practices in cellular therapy to transfusion professionals. Please find below some topics where we work on supporting you with material and ideas. Please click on the below links to read more about the Working Party activities. 

Human Platelet Lysate

Autologous Serum Eye drops

Unproven Cellular Therapies

Biobanking for Therapeutic Purposes

Publications

  1. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applicationsKenneth W. Witwer, Bas W.M. Van Balkom, Stefania Brunod, Andre Choo, Massimo Dominici, Mario Gimona, Andrew F. Hill, Dominique De Kleijn, Mickey Koh, Ruenn Chai Lai, S. Alex Mitsialis, Luis A. Ortiz, Eva Rohde, Takashi Asada, Wei Seong Toh, Daniel J. WeisJournal of Extracellular Vesicles
  1. Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardizationM.L. Chou, T. BurnoufISBT Science Series
  2. A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells Lassina Barro, Yu‐Ting Su, Ouada Nebie, Yu‐Wen Wu, Yen‐Hua Huang, Mickey BC Koh, Folke Knutson, Thierry BurnoufTransfusion
  3. Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cellsMing-ShengChena, Tsung-Jen Wang, Hsiu-Chen Linde, Thierry BurnoufNew Biotechnology
  4. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways Flore Gouel, Bruce Do Van, Ming‐Li Chou, Aurélie Jonneaux, Caroline Moreau, Régis Bordet, Thierry Burnouf, Jean‐Christophe Devedjian, David DevosTissue Engineering and Regenerative Medicine
  5. International Forum on GMP-grade human platelet lysate for cell propagation: summaryD. Strunk, M. Lozano, D.C. Marks, Y. S. Loh, G. Gstraunthaler, H. Schennach, E. Rohde, S. Laner‐Plamberger, M. Öller, J. Nystedt, R. Lotfi, M. Rojewski, H. Schrezenmeier, K. Bieback, R. Schäfer, T. Bakchoul, M. Waidmann, S.M. Jonsdottir‐Buch, H. MonVox Sanguinis
  6. Multifaceted regenerative lives of ‘expired’ plateletsT BurnoufISBT Science Series
  7. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansionDaniel Tzu-Bi Shih, Thierry BurnoufNew Technology
  8. Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography Ming Li Chou, Andy Bailey, Tiffany Avory, Junji Tanimoto, Thierry BurnoufPlos One
  9. Human platelet lysate current standards and future developmentsReinhard Henschler, Christian Gabriel, Katharina Schallmoser, Thierry Burnouf and Mickey B.C. KohTransfusion
  10. Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's diseaseMing-Li Chou, Joe-Wei Wu, Flore Gouel, Aurelie Jonneaux, Kelly Timmerman, Ting-Yi Renn, Charlotte Laloux, Hung-Ming Chang, Liang-Tzung Lin, Jean-Christophe Devedjian, David Devos, Thierry BurnoufBiomaterials
  11. The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTHP. Harrison for the subcommittee on Platelet Physiology Journal of Thrombosis and Haemostasis
  12. Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansionYU-CHUN KAO, ANDY BAILEY, BERNHARD SAMMINGER, JUNJI TANIMOTO, THIERRY BURNOUFCytotherapy
  1. Human platelet lysate current standards and future developments Reinhard Henschler, Christian Gabriel, Katharina Schallmoser, Thierry Burnouf, Mickey B.C. KohTransfusion

Useful links and cooperations

AABB Center for Cellular Therapies

International Society for Cell Therapy

Joint Accrediation Committee of EBMT & ISBT

Worldwide Network for Blood & Marrow Transplantation (WBMT)

 

Upcoming events organized by the Working Party

Eye Drops from Human Origin - First EDHO Workshop on Current Standards and Future Developments March 19-20, 2020 is postponed and will be held on March 25 and 26, 2021 in Vienna, Austria. 

GET IN TOUCH

Mickey Koh

Mickey Koh

Chairperson

E-mail
St. Georges Hospital & Medical School
Stem cell transplantation
London, UK

OTHER WORKING PARTIES